Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Investigation

• Publication date

  2016-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI84940PMID 27159395PMCID PMC4887167
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Perspectives on Cost and Value in Cancer Care.

  2016cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.

  2015cited by this paper
• Robust enumeration of cell subsets from tissue expression profiles

  2015cited by this paper
• Association of POLE-mutated and MSI endometrial cancers with an elevated number of tumor-infiltrating and peritumoral lymphocytes and higher expression of PD-L1.

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

  2015cited by this paper
• Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations

  2015cited by this paper
• Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

  2015cited by this paper
• Polymerase ɛ (POLE) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing

  2015cited by this paper
• Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028.

  2015cited by this paper
• Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study.

  2015cited by this paper
• Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Replicative DNA polymerase mutations in cancer☆

  2014cited by this paper
• Integrated genomic characterization of endometrial carcinoma

  2013influential reference
• SUPPLEMENTARY NOTE

  1879cited by this paper

• Phenotypic POLE variant classification identifies patients who may have favorable prognosis and benefit from immunotherapy.

  2026cites this paper
• Prognostic Impact of POLE Exonuclease-Domain Mutations in Endometrial Cancer: A Systematic Review and Meta-Analysis.

  2026cites this paper
• POLE-mutated endometrial cancer: new perspectives on the horizon?

  2025cites this paper
• Intra-Tumoral Lymphocytic Infiltration Is Associated with Favorable Prognosis in Suboptimal Surgery in High-Grade Serous Ovarian Carcinoma

  2025cites this paper
• Comprehensive Review of Endometrial Cancer: New Molecular and FIGO Classification and Recent Treatment Changes

  2025cites this paper
• A Deeper Dive into POLE-Mutated Endometrial Carcinomas: The Contributions and Consequences of Tumor Mutational Burden.

  2025cites this paper
• Subclonal loss of DNA mismatch repair proteins in endometrial carcinomas: an unusual pattern with distinct molecular characteristics.

  2025cites this paper
• Characterization of T cell markers in endometrial carcinoma through single-cell RNA sequencing

  2025cites this paper
• Of Context, Quality, and Complexity: Fine-combing Tumor Mutation Burden in Immunotherapy Treated Cancers.

  2025cites this paper
• The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers

  2025cites this paper
• Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights

  2025cites this paper
• Unveiling immunogenic characteristics and neoantigens in endometrial cancer with POLE hotspot mutations for improved immunotherapy

  2025cites this paper
• Immunogenomic precision medicine: a personalized approach based on immunogenomic cancer evolution.

  2025cites this paper
• Predictive Biomarkers for Immunotherapy in Endometrial Carcinoma

  2025influential citation
• Genome instability and crosstalk with the immune response

  2025cites this paper
• Beyond the Microscope: Integrating Liquid Biopsies into the Molecular Pathology Era of Endometrial Cancer

  2025cites this paper
• Complete response of somatic POLE-ultramutated recurrent undifferentiated uterine sarcoma to pembrolizumab and concurrent radiotherapy

  2025cites this paper
• Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy.

  2025cites this paper
• Immune checkpoint inhibitors in colorectal cancer: limitation and challenges

  2024cites this paper
• Shared Pathogenic and Therapeutic Characteristics of Endometriosis, Adenomyosis, and Endometrial Cancer: A Comprehensive Literature Review

  2024cites this paper
• Next-generation sequencing in the molecular classification of endometrial carcinomas: Experience with 270 cases suggesting a potentially more aggressive clinical behavior of multiple classifier endometrial carcinomas

  2024cites this paper
• POLE-mutated uterine carcinosarcomas: a clinicopathologic and molecular study of 11 cases.

  2024cites this paper
• Emerging applications of hypomethylating agents in the treatment of glioblastoma (Review)

  2024cites this paper
• The Clinical and Pathological Characteristics of POLE-Mutated Endometrial Cancer: A Comprehensive Review

  2024cites this paper
• Progress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer

  2024cites this paper
• Patterns of cytotoxic T-cell densities in immunogenic endometrial cancers reveal a potential mechanism for differences in immunotherapy efficacy

  2024cites this paper
• Tumoral programmed cell death 1 (PD1) expression in endometrial carcinoma is a prognostic marker for patient outcome

  2024cites this paper
• Landscape of Endometrial Cancer: Molecular Mechanisms, Biomarkers, and Target Therapy

  2024cites this paper
• The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway

  2024cites this paper
• Novel Molecular Targets in Endometrial Cancer: Mechanisms and Perspectives for Therapy

  2024cites this paper
• Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial Cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications

  2024cites this paper
• Prognostic significance of the immune microenvironment in endometrial cancer.

  2024cites this paper
• Enhancing the detection of clinically relevant biomarkers in advanced uterine and tubo-ovarian carcinomas through genome-wide analysis.

  2024cites this paper
• MRI-based radiomics model for predicting endometrial cancer with high tumor mutation burden

  2024cites this paper
• Pyroptosis-associated genes and tumor immune response in endometrial cancer

  2024cites this paper
• Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer.

  2024cites this paper
• Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes

  2024cites this paper
• Low-Risk and High-Risk NSMPs: A Prognostic Subclassification of No Specific Molecular Profile Subtype of Endometrial Carcinomas

  2024cites this paper
• Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer

  2023cites this paper
• Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype.

  2023cites this paper
• POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval

  2023cites this paper
• Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors

  2023cites this paper
• A pathway-based mutation signature to predict the clinical outcomes and response to CTLA-4 inhibitors in melanoma.

  2023cites this paper
• A comprehensive analysis of immunotherapy in advanced endometrial cancer (Review).

  2023cites this paper
• Biomarkers to guide immunomodulatory treatment: where do we stand?

  2023cites this paper
• SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy

  2023cites this paper
• Mutational Signatures in Gastric Cancer and Their Clinical Implications

  2023cites this paper
• Bibliometric and visualized analysis of the top-100 highly cited articles on immunotherapy for endometrial cancer

  2023cites this paper
• Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1

  2023cites this paper
• Current Methods and Advances in the Immunotherapy Treatment of Non-Ovarian Gynaecological Cancers

  2023cites this paper
• A novel integrated approach to predicting cancer immunotherapy efficacy

  2023cites this paper
• The Clinicopathological Characteristics of POLE-mutated Colorectal Cancer and the Prognostic Value of POLE Status.

  2023cites this paper
• Immunologic Signatures across Molecular Subtypes and Potential Biomarkers for Sub-Stratification in Endometrial Cancer

  2023influential citation
• Case report: POLE (P286R) mutation in a case of recurrent intestinal leakage and its treatment

  2023cites this paper
• Cadonilimab plus anlotinib effectively relieve rare cardiac angiosarcoma with multiple metastases: a case report and literature review

  2023cites this paper
• Computational Methods Summarizing Mutational Patterns in Cancer: Promise and Limitations for Clinical Applications

  2023cites this paper
• An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy

  2023cites this paper
• Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis

  2022cites this paper
• Combining concurrent radiotherapy and immunotherapy for synergistic effects in recurrent endometrial cancer – A case report

  2022cites this paper
• Interplay between the DNA Damage Response and Immunotherapy Response in Cancer

  2022influential citation
• The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients

  2022cites this paper
• Endometrial cancer: molecular classification and future treatments

  2022cites this paper
• Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

  2022cites this paper
• A novel pathway mutation perturbation score predicts the clinical outcomes of immunotherapy

  2022cites this paper
• The DNA damage induced immune response: Implications for cancer therapy.

  2022cites this paper
• Diagnostic and Prognostic Biomarkers in Renal Clear Cell Carcinoma

  2022cites this paper
• Biomarqueurs en immunothérapie, signatures moléculaires, radiomique : avons-nous avancé ?

  2022cites this paper
• Hereditary Colorectal Cancer Syndromes: Molecular Genetics and Precision Medicine

  2022cites this paper
• To Identify Adenomatous Polyposis Coli Gene Mutation as a Predictive Marker of Endometrial Cancer Immunotherapy

  2022cites this paper
• Mutational Signatures Associate With Survival in Gastrointestinal Carcinomas

  2022cites this paper
• Exploring immunotherapy in colorectal cancer

  2022cites this paper
• Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity

  2022cites this paper
• Facts and hopes in immunotherapy of endometrial cancer.

  2022cites this paper
• Enhanced polymerase activity permits efficient synthesis by cancer-associated DNA polymerase ϵ variants at low dNTP levels

  2022cites this paper
• Incorporating Molecular Diagnostics into Treatment Paradigms for Endometrial Cancer

  2022cites this paper
• Mutations in Homologous Recombination Repair Genes in Colorectal Cancer Are Associated With Favorable Response to Immune Checkpoint Inhibitors

  2022cites this paper
• An autologous dendritic cell vaccine promotes anticancer immunity in ovarian cancer patients with low mutational burden and cold tumors.

  2022cites this paper
• Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes

  2022cites this paper
• Association of KDR mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors.

  2022cites this paper
• L1CAM expression as a predictor of platinum response in high‐risk endometrial carcinoma

  2022cites this paper
• Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer

  2022influential citation
• Endometrial Cancer-Infiltrating Mesenchymal Stem Cells Exhibit Immunosuppressive Effects

  2022cites this paper
• A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response

  2022cites this paper
• Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit

  2022cites this paper
• Polymerase Epsilon-Associated Ultramutagenesis in Cancer

  2022cites this paper
• Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer

  2022cites this paper
• A Gene Panel for Early Identification of Future Responders to Immune Checkpoint Blockade

  2022cites this paper
• Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma

  2022cites this paper
• Couverture

  2022cites this paper
• Biomarkers for predicting the efficacy of immune checkpoint inhibitors

  2022cites this paper
• Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis

  2022cites this paper
• Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast Cancer.

  2022cites this paper
• Emerging Treatment Options for Advanced or Recurrent Endometrial Cancer

  2022cites this paper
• Endometrial Cancer: An Update on Prognostic Pathologic Features and Clinically Relevant Biomarkers.

  2022cites this paper
• Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types

  2022cites this paper
• Retraction Retracted: DNA Damage Response Genes in Osteosarcoma

  2022cites this paper
• The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer

  2021cites this paper
• Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy

  2021cites this paper
• Targeting the DNA damage response in immuno-oncology: developments and opportunities

  2021cites this paper
• Nodular fasciitis: a comprehensive, time-correlated investigation of 17 cases

  2021cites this paper